Shields P G, Ambrosone C B, Graham S, Bowman E D, Harrington A M, Gillenwater K A, Marshall J R, Vena J E, Laughlin R, Nemoto T, Freudenheim J L
Laboratory of Human Carcinogenesis, National Cancer Institute, Bethesda, Maryland 20892, USA.
Mol Carcinog. 1996 Nov;17(3):144-50. doi: 10.1002/(SICI)1098-2744(199611)17:3<144::AID-MC6>3.0.CO;2-F.
Known breast-cancer risk factors account for only part of the variability in breast-cancer incidence. Tobacco smoke is not commonly considered a breast carcinogen, but many of its constituents, such as N-nitrosamines, are carcinogenic in laboratory animal studies. Herein, we assessed a cytochrome P4502E1 (CYP2E1) genetic polymorphism (a Dral restriction enzyme site in intron 6) as a risk factor for breast cancer in both premenopausal and postmenopausal women. Because N-nitrosamines are metabolically activated by CYP2E1, the risk among women smokers was investigated. Caucasian women were enrolled in a case-control study of breast cancer between 1986 and 1991. A subset of the women (219 premenopausal and 387 postmenopausal women) consented to phlebotomy. The allelic frequencies for the premenopausal women (D allele = 0.91 and C allele = 0.09) and postmenopausal women (D allele = 0.93 and C allele = 0.07) were similar to those previously reported. There was no statistically significant association between the CYP2E1 polymorphism and breast-cancer risk for premenopausal or postmenopausal women (adjusted odds ratio (OR) = 1.04, 95% confidence interval (CI) = 0.48, 2.24, and OR = 1.01, 95% CI = 0.55, 1.84, respectively). When the women were categorized as nonsmokers versus smokers (those who smoked more than one cigarette per week for more than 1 yr), premenopausal women with one or two C alleles who had a history of smoking were found to be at increased risk (unadjusted OR = 7.00, 95% CI = 0.75, 14.53, and adjusted OR = 11.09, 95% CI = 1.51, 81.41), although the number of study subjects with those genotypes was small. The small number of study subjects with a C allele precluded meaningful classification by level of smoking, but categorizing the smokers into two groups (above and below the median) also suggested an increased risk. Premenopausal women with the DD genotype and postmenopausal women with any genotype were not at increased risk. Breast-cancer risk was not related to the CYP2E1 genotype in either premenopausal nonsmokers or smokers (adjusted OR = 0.66, 95% CI = 0.20, 2.17, and OR = 2.13, 95% CI = 0.60, 7.59, respectively) or postmenopausal nonsmokers or smokers (OR = 0.90, 95% CI = 0.34, 2.35, and OR = 1.02, 95% CI = 0.46, 2.23, respectively), although the difference in the ORs for premenopausal nonsmokers and smokers suggests an increased risk for smokers. While there are limitations to this study, particularly related to the small number of subjects with the DC and CC genotypes, the study suggests that some women may be susceptible to tobacco smoke because of a CYP2E1 polymorphism. However, these results are preliminary and must be replicated.
已知的乳腺癌风险因素仅能解释部分乳腺癌发病率的变异性。烟草烟雾通常不被视为乳腺癌致癌物,但其许多成分,如N - 亚硝胺,在实验室动物研究中具有致癌性。在此,我们评估了细胞色素P4502E1(CYP2E1)基因多态性(第6内含子中的一个Dral限制性酶切位点)作为绝经前和绝经后女性患乳腺癌的风险因素。由于N - 亚硝胺通过CYP2E1进行代谢激活,因此对女性吸烟者的风险进行了调查。1986年至1991年期间,白人女性被纳入一项乳腺癌病例对照研究。部分女性(219名绝经前女性和387名绝经后女性)同意接受静脉穿刺采血。绝经前女性(D等位基因 = 0.91,C等位基因 = 0.09)和绝经后女性(D等位基因 = 0.93,C等位基因 = 0.07)的等位基因频率与先前报道的相似。CYP2E1基因多态性与绝经前或绝经后女性患乳腺癌风险之间无统计学显著关联(调整后的优势比(OR)= 1.04,95%置信区间(CI)= 0.48,2.24;以及OR = 1.01,95% CI = 0.55,1.84)。当将女性分为非吸烟者与吸烟者(每周吸烟超过1支且超过1年者)时,发现有吸烟史且携带一个或两个C等位基因的绝经前女性风险增加(未调整的OR = 7.00,95% CI = 0.75,14.53;调整后的OR = 11.09,95% CI = 1.51,81.41),尽管具有这些基因型的研究对象数量较少。携带C等位基因的研究对象数量较少,无法按吸烟水平进行有意义的分类,但将吸烟者分为两组(中位数以上和以下)也表明风险增加。具有DD基因型的绝经前女性和任何基因型的绝经后女性风险未增加。绝经前非吸烟者或吸烟者(调整后的OR = 0.66,95% CI = 0.20,2.17;以及OR =